Beyond Air® Submits Premarket Approval Application to FDA for LungFit™ PH to Treat Persistent Pulmonary Hypertension of the Newborn

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/8/2026

1. IONQ
2. SPY
3. ROIV
4. AAPL
5. ACN
6. IONS
7. AZN
8. ORCL
9. HOOD
10. QCOM

Go back to Beyond Air® Submits Premarket Approval Application to FDA for LungFit™ PH to Treat Persistent Pulmonary Hypertension of the Newborn
(NASDAQ: XAIR) Delayed: 3.47 -0.06 (1.7%)
Previous Close $3.53    52 Week High $ 
Open $3.51    52 Week Low $ 
Day High $3.58    P/E N/A 
Day Low $3.47    EPS $ 
Volume 32,831